Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness

D L Roelen, E L Dover, M Niimi, Neil Thomas Young, P J Morris, K J Wood

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The beneficial effect on graft survival achieved by pretransplant blood transfusions is well established. However, the type of major histocompatibility complex (MHC) mismatch between transfusion donor and recipient seems to play a role in determining the outcome. The hypothesis that this sharing of MHC antigens is correlated with the level of sensitization or tolerization was studied in mice by pretreatment with semi-allogeneic (F1) or with fully allogeneic whole blood transfusions. Limiting dilution analysis (LDA) in vitro for donor-specific T helper (Thp) and cytotoxic T lymphocyte precursors (CTLp) performed on splenocytes isolated from transfused recipients 2 or 4 weeks after transfusion showed that the duration and magnitude of the response was reduced after a semi-allogeneic compared to a fully allogeneic transfusion. After a semi-allogeneic transfusion, both Thp and CTLp frequencies had returned to naive levels 4 weeks after transfusion, whereas after infusion of fully allogeneic blood, they remained elevated after 4 weeks. When a fully allogeneic heart was transplanted 2 or 4 weeks after transfusion, a small but significant improvement in graft prolongation (2 weeks, not significant, 4 weeks: p <0.01) was observed following pretreatment with a semi-allogeneic transfusion (2 weeks: median survival time (MST) 30 days, 4 weeks: MST 29 days) compared to that obtained after fully allogeneic transfusion (2 weeks: MST 23 days, 4 weeks: MST 12 days). The semi-allogeneic transfusions were correlated with a statistically significant prolonged (7 days) persistence of donor-derived MHC class II+ cells in the recipient and with reduced levels of anti-donor MHC class I-specific antibody formation compared to these responses after transfusion with fully allogeneic cells. These results demonstrate that pretreatment with a semi-allogeneic blood transfusion is more tolerizing and less sensitizing than pretreatment with a fully allogeneic blood transfusion. These findings may be explained by the sharing of MHC antigens between recipient and transfusion donor.
Original languageEnglish
Pages (from-to)1468-1474
Number of pages7
JournalEuropean Journal of Immunology
Volume26
Issue number7
DOIs
Publication statusPublished - 1 Jul 1996

Fingerprint

Major Histocompatibility Complex
Blood Transfusion
Histocompatibility Antigens
Cytotoxic T-Lymphocytes
Helper-Inducer T-Lymphocytes
Graft Survival
Antibody Formation
Transplants

Keywords

  • Animals
  • Antibody Formation
  • Antibody Specificity
  • Blood Donors
  • Blood Transfusion
  • Graft Enhancement, Immunologic
  • Heart Transplantation
  • Immune Tolerance
  • Immunity, Cellular
  • Isoantigens
  • Lymphoma, T-Cell
  • Mast-Cell Sarcoma
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Transplantation, Homologous
  • Tumor Cells, Cultured

Cite this

Semi-allogeneic (F1) versus fully allogeneic blood transfusions : differences in their ability to induce specific immunological unresponsiveness. / Roelen, D L; Dover, E L; Niimi, M; Young, Neil Thomas; Morris, P J; Wood, K J.

In: European Journal of Immunology, Vol. 26, No. 7, 01.07.1996, p. 1468-1474.

Research output: Contribution to journalArticle

Roelen, D L ; Dover, E L ; Niimi, M ; Young, Neil Thomas ; Morris, P J ; Wood, K J. / Semi-allogeneic (F1) versus fully allogeneic blood transfusions : differences in their ability to induce specific immunological unresponsiveness. In: European Journal of Immunology. 1996 ; Vol. 26, No. 7. pp. 1468-1474.
@article{7f7dd5bbef8b4d79899acc8c9d65e43b,
title = "Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness",
abstract = "The beneficial effect on graft survival achieved by pretransplant blood transfusions is well established. However, the type of major histocompatibility complex (MHC) mismatch between transfusion donor and recipient seems to play a role in determining the outcome. The hypothesis that this sharing of MHC antigens is correlated with the level of sensitization or tolerization was studied in mice by pretreatment with semi-allogeneic (F1) or with fully allogeneic whole blood transfusions. Limiting dilution analysis (LDA) in vitro for donor-specific T helper (Thp) and cytotoxic T lymphocyte precursors (CTLp) performed on splenocytes isolated from transfused recipients 2 or 4 weeks after transfusion showed that the duration and magnitude of the response was reduced after a semi-allogeneic compared to a fully allogeneic transfusion. After a semi-allogeneic transfusion, both Thp and CTLp frequencies had returned to naive levels 4 weeks after transfusion, whereas after infusion of fully allogeneic blood, they remained elevated after 4 weeks. When a fully allogeneic heart was transplanted 2 or 4 weeks after transfusion, a small but significant improvement in graft prolongation (2 weeks, not significant, 4 weeks: p <0.01) was observed following pretreatment with a semi-allogeneic transfusion (2 weeks: median survival time (MST) 30 days, 4 weeks: MST 29 days) compared to that obtained after fully allogeneic transfusion (2 weeks: MST 23 days, 4 weeks: MST 12 days). The semi-allogeneic transfusions were correlated with a statistically significant prolonged (7 days) persistence of donor-derived MHC class II+ cells in the recipient and with reduced levels of anti-donor MHC class I-specific antibody formation compared to these responses after transfusion with fully allogeneic cells. These results demonstrate that pretreatment with a semi-allogeneic blood transfusion is more tolerizing and less sensitizing than pretreatment with a fully allogeneic blood transfusion. These findings may be explained by the sharing of MHC antigens between recipient and transfusion donor.",
keywords = "Animals, Antibody Formation, Antibody Specificity, Blood Donors, Blood Transfusion, Graft Enhancement, Immunologic, Heart Transplantation, Immune Tolerance, Immunity, Cellular, Isoantigens, Lymphoma, T-Cell, Mast-Cell Sarcoma, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Inbred C57BL, Transplantation, Homologous, Tumor Cells, Cultured",
author = "Roelen, {D L} and Dover, {E L} and M Niimi and Young, {Neil Thomas} and Morris, {P J} and Wood, {K J}",
year = "1996",
month = "7",
day = "1",
doi = "10.1002/eji.1830260710",
language = "English",
volume = "26",
pages = "1468--1474",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "7",

}

TY - JOUR

T1 - Semi-allogeneic (F1) versus fully allogeneic blood transfusions

T2 - differences in their ability to induce specific immunological unresponsiveness

AU - Roelen, D L

AU - Dover, E L

AU - Niimi, M

AU - Young, Neil Thomas

AU - Morris, P J

AU - Wood, K J

PY - 1996/7/1

Y1 - 1996/7/1

N2 - The beneficial effect on graft survival achieved by pretransplant blood transfusions is well established. However, the type of major histocompatibility complex (MHC) mismatch between transfusion donor and recipient seems to play a role in determining the outcome. The hypothesis that this sharing of MHC antigens is correlated with the level of sensitization or tolerization was studied in mice by pretreatment with semi-allogeneic (F1) or with fully allogeneic whole blood transfusions. Limiting dilution analysis (LDA) in vitro for donor-specific T helper (Thp) and cytotoxic T lymphocyte precursors (CTLp) performed on splenocytes isolated from transfused recipients 2 or 4 weeks after transfusion showed that the duration and magnitude of the response was reduced after a semi-allogeneic compared to a fully allogeneic transfusion. After a semi-allogeneic transfusion, both Thp and CTLp frequencies had returned to naive levels 4 weeks after transfusion, whereas after infusion of fully allogeneic blood, they remained elevated after 4 weeks. When a fully allogeneic heart was transplanted 2 or 4 weeks after transfusion, a small but significant improvement in graft prolongation (2 weeks, not significant, 4 weeks: p <0.01) was observed following pretreatment with a semi-allogeneic transfusion (2 weeks: median survival time (MST) 30 days, 4 weeks: MST 29 days) compared to that obtained after fully allogeneic transfusion (2 weeks: MST 23 days, 4 weeks: MST 12 days). The semi-allogeneic transfusions were correlated with a statistically significant prolonged (7 days) persistence of donor-derived MHC class II+ cells in the recipient and with reduced levels of anti-donor MHC class I-specific antibody formation compared to these responses after transfusion with fully allogeneic cells. These results demonstrate that pretreatment with a semi-allogeneic blood transfusion is more tolerizing and less sensitizing than pretreatment with a fully allogeneic blood transfusion. These findings may be explained by the sharing of MHC antigens between recipient and transfusion donor.

AB - The beneficial effect on graft survival achieved by pretransplant blood transfusions is well established. However, the type of major histocompatibility complex (MHC) mismatch between transfusion donor and recipient seems to play a role in determining the outcome. The hypothesis that this sharing of MHC antigens is correlated with the level of sensitization or tolerization was studied in mice by pretreatment with semi-allogeneic (F1) or with fully allogeneic whole blood transfusions. Limiting dilution analysis (LDA) in vitro for donor-specific T helper (Thp) and cytotoxic T lymphocyte precursors (CTLp) performed on splenocytes isolated from transfused recipients 2 or 4 weeks after transfusion showed that the duration and magnitude of the response was reduced after a semi-allogeneic compared to a fully allogeneic transfusion. After a semi-allogeneic transfusion, both Thp and CTLp frequencies had returned to naive levels 4 weeks after transfusion, whereas after infusion of fully allogeneic blood, they remained elevated after 4 weeks. When a fully allogeneic heart was transplanted 2 or 4 weeks after transfusion, a small but significant improvement in graft prolongation (2 weeks, not significant, 4 weeks: p <0.01) was observed following pretreatment with a semi-allogeneic transfusion (2 weeks: median survival time (MST) 30 days, 4 weeks: MST 29 days) compared to that obtained after fully allogeneic transfusion (2 weeks: MST 23 days, 4 weeks: MST 12 days). The semi-allogeneic transfusions were correlated with a statistically significant prolonged (7 days) persistence of donor-derived MHC class II+ cells in the recipient and with reduced levels of anti-donor MHC class I-specific antibody formation compared to these responses after transfusion with fully allogeneic cells. These results demonstrate that pretreatment with a semi-allogeneic blood transfusion is more tolerizing and less sensitizing than pretreatment with a fully allogeneic blood transfusion. These findings may be explained by the sharing of MHC antigens between recipient and transfusion donor.

KW - Animals

KW - Antibody Formation

KW - Antibody Specificity

KW - Blood Donors

KW - Blood Transfusion

KW - Graft Enhancement, Immunologic

KW - Heart Transplantation

KW - Immune Tolerance

KW - Immunity, Cellular

KW - Isoantigens

KW - Lymphoma, T-Cell

KW - Mast-Cell Sarcoma

KW - Mice

KW - Mice, Inbred BALB C

KW - Mice, Inbred C3H

KW - Mice, Inbred C57BL

KW - Transplantation, Homologous

KW - Tumor Cells, Cultured

U2 - 10.1002/eji.1830260710

DO - 10.1002/eji.1830260710

M3 - Article

C2 - 8766548

VL - 26

SP - 1468

EP - 1474

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 7

ER -